Lantheus Holdings, Inc. (LNTH) News



Lantheus Holdings, Inc. (LNTH)

Today's Latest Price: $15.83 USD

0.13 (-0.81%)

Updated Jan 25 9:59am

Add LNTH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

StocksNews Articles for LNTH

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest LNTH News From Around the Web

Below are the latest news stories about Lantheus Holdings Inc that investors may wish to consider to help them evaluate LNTH as an investment opportunity.

Lantheus files U.S. application for PD-L1 imaging biomarker

Lantheus ([[LNTH]] +4.0%) has filed a Drug Master File with the FDA for NM-01, a PD-L1 imaging biomarker, and will begin making the biomarker available to academic centers and pharmaceutical companies for use in immuno-oncology trials in 2021.NM-01 is a proprietary radiopharmaceutical biomarker using a camelid single-domain antibody and a technetium-99...

Seeking Alpha | January 12, 2021

Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for NM-01, a PD-L1 imaging biomarker, and will begin making the biomarker avail

Business Wire | January 12, 2021

Is LNTH A Good Stock To Buy Now?

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | December 15, 2020

Nuclear Medicine Market Booming Worldwide Opportunity, Upcoming Trends and Growth Forecast 2030 |orthStar Medical Radioisotopes LLC, Progenics Pharmaceuticals Inc., Bracco S.p.A., Curium Pharma, Life Molecular Imaging, Bayer AG, Lantheus Holdings Inc

The Nuclear Medicine/Radiopharmaceuticals Market was worth US$ 6.5 Billion in 2019 and is expected to grow at a CAGR of 8.9% through 2030. The major factor driving the growth of global market is the increasing prevalence of cancer patients across

OpenPR | December 11, 2020

PyL™ (18F-DCFPyL), Lantheus’ PSMA-Targeted Prostate Cancer Imaging Agent, to be Used in POINT Biopharma’s PSMA-Targeted Radioligand Therapeutic Phase 3 Trial in Patients with Metastatic Castration Resistant Prostate Cancer

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it has entered into a strategic collaboration with POINT Biopharma, Inc. (POINT) to use Lantheus’ investigational prostate-specific membrane antigen (PSMA)-targeted positron emi

Business Wire | December 9, 2020

Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (the Company), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for PyLTM (18F-DCFPyL), a prostate specific membrane antigen (PSMA)-t

Business Wire | December 9, 2020

Lantheus Holdings, Inc. Announces Agreement to Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility and Enter into Long-Term Supply Agreement

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (the Company), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced its entry into a stock purchase agreement to sell its Puerto Rico radiopharmacy and positron emission tomography (PET) manufacturing facility (PMF) to PharmaLogic

Business Wire | December 3, 2020

Lantheus Holdings to Present at the 2020 Evercore ISI HealthCONx Conference

Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the 2020 Evercore ISI HealthCONx Conference at 3:30 p.m. ET on Tuesday, December 1.

Yahoo | November 24, 2020

Microbubbles / Ultrasound Contrast Agents Market Rapidly Growing in Healthcare Sector by 2020-2027 with Leading Firms: Lantheus Holdings, Inc., Bracco, GE Healthcare, Daiichi Sankyo Company, Limited, and nanoPET Pharma GmbH

Global Microbubbles/Ultrasound Contrast Agents Market is expected to reach USD 1,584.5 million by 2027, at a CAGR of +25% during the forecast period of 2020 to 2027. A new report has been added by Report Consultant on the global Microbubbles /

OpenPR | November 23, 2020

Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY® Room Temperature

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for DEFINITY® Room Temperature (DEFINITY RT) (Perflutren L

Business Wire | November 18, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5798 seconds.